ATRX and Its Prognostic Significance in Soft Tissue Sarcoma.

Q2 Medicine

Sarcoma Pub Date : 2024-05-06 eCollection Date: 2024-01-01 DOI:10.1155/2024/4001796

Mark M Cullen, Warren Floyd, Bobby Dow, Beatrice Schleupner, Brian E Brigman, Julia D Visgauss, Diana M Cardona, Jason A Somarelli, William C Eward

{"title":"ATRX and Its Prognostic Significance in Soft Tissue Sarcoma.","authors":"Mark M Cullen, Warren Floyd, Bobby Dow, Beatrice Schleupner, Brian E Brigman, Julia D Visgauss, Diana M Cardona, Jason A Somarelli, William C Eward","doi":"10.1155/2024/4001796","DOIUrl":null,"url":null,"abstract":"Purpose: Recently, the association between ATRX and a more aggressive sarcoma phenotype has been shown. We performed a retrospective study of sarcomas from an individual institution to evaluate ATRX as a prognosticator in soft tissue sarcoma. Experimental Design. 128 sarcomas were collected from a single institution and stained for ATRX. The prognostic significance of these markers was evaluated in a smaller cohort of primary soft tissue sarcomas (n = 68). Kaplan-Meier curves were created for univariate analysis, and Cox regression was utilized for multivariate analysis.Results: High expression of ATRX was found to be a positive prognostic indicator for overall survival and metastasis-free survival in our group of soft tissue sarcomas both in univariate analysis and multivariate analysis (HR: 0.38 (0.17-0.85), P=0.02 and HR: 0.49 (0.24-0.99), P=0.05, respectively).Conclusions: High expression of ATRX is a positive prognostic indicator of overall survival and metastasis-free survival in patients with STS. This is consistent with studies in osteosarcoma, which indicate possible mechanisms through which loss of ATRX leads to more aggressive phenotypes. Future prospective clinical studies are required to validate the prognostic significance of these findings.","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"2024 ","pages":"4001796"},"PeriodicalIF":0.0000,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11090676/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sarcoma","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2024/4001796","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Recently, the association between ATRX and a more aggressive sarcoma phenotype has been shown. We performed a retrospective study of sarcomas from an individual institution to evaluate ATRX as a prognosticator in soft tissue sarcoma. Experimental Design. 128 sarcomas were collected from a single institution and stained for ATRX. The prognostic significance of these markers was evaluated in a smaller cohort of primary soft tissue sarcomas (n = 68). Kaplan-Meier curves were created for univariate analysis, and Cox regression was utilized for multivariate analysis.

Results: High expression of ATRX was found to be a positive prognostic indicator for overall survival and metastasis-free survival in our group of soft tissue sarcomas both in univariate analysis and multivariate analysis (HR: 0.38 (0.17-0.85), P=0.02 and HR: 0.49 (0.24-0.99), P=0.05, respectively).

Conclusions: High expression of ATRX is a positive prognostic indicator of overall survival and metastasis-free survival in patients with STS. This is consistent with studies in osteosarcoma, which indicate possible mechanisms through which loss of ATRX leads to more aggressive phenotypes. Future prospective clinical studies are required to validate the prognostic significance of these findings.

查看原文本刊更多论文

ATRX 及其在软组织肉瘤中的预后意义

目的最近，ATRX 与更具侵袭性的肉瘤表型之间存在关联。我们对一家机构的肉瘤进行了回顾性研究，以评估 ATRX 作为软组织肉瘤预后指标的作用。实验设计。我们从一家机构收集了 128 例肉瘤，并对其进行了 ATRX 染色。在一个较小的原发性软组织肉瘤群（n = 68）中评估了这些标记物的预后意义。单变量分析采用Kaplan-Meier曲线，多变量分析采用Cox回归法：结果：在本组软组织肉瘤中，ATRX的高表达在单变量分析和多变量分析中均被认为是总生存期和无转移生存期的积极预后指标（HR：0.38 (0.17-0.85)，P=0.02；HR：0.49 (0.24-0.99)，P=0.05）：ATRX的高表达是STS患者总生存率和无转移生存率的一个积极预后指标。结论：ATRX的高表达是STS患者总生存期和无转移生存期的积极预后指标，这与骨肉瘤研究结果一致，表明ATRX的缺失可能导致更具侵袭性的表型。未来还需要进行前瞻性临床研究来验证这些发现的预后意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Sarcoma Medicine-Radiology, Nuclear Medicine and Imaging

CiteScore

5.00

自引率

0.00%

发文量

审稿时长

14 weeks

期刊介绍： Sarcoma is dedicated to publishing papers covering all aspects of connective tissue oncology research. It brings together work from scientists and clinicians carrying out a broad range of research in this field, including the basic sciences, molecular biology and pathology and the clinical sciences of epidemiology, surgery, radiotherapy and chemotherapy. High-quality papers concerning the entire range of bone and soft tissue sarcomas in both adults and children, including Kaposi"s sarcoma, are published as well as preclinical and animal studies. This journal provides a central forum for the description of advances in diagnosis, assessment and treatment of this rarely seen, but often mismanaged, group of patients.